Open AccessIxazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma
Author(s) -
Roman Hájek,
Jiří Minařík,
Jan Štraub,
Luděk Pour,
Alexandra Jungová,
Jesús G. Berdeja,
Mario Boccadoro,
Lucie Brožová,
Andrew Spencer,
Frits van Rhee,
Jorge VelaOjeda,
Michael A. Thompson,
Rafat Abonour,
Ajai Chari,
Gordon Cook,
Caitlin Costello,
Faith E. Davies,
Vânia Hungria,
Hans C. Lee,
Xavier Leleu,
Noemí Puig,
Robert M. Rifkin,
Evangelos Terpos,
Saad Z. Usmani,
Katja Weisel,
Jeffrey A. Zonder,
Magda Bařinová,
Matyáš Kuhn,
Jiří Šilar,
Lenka Čápková,
Kenny Gálvez,
Jin Lu,
Jennifer Elliott,
Dawn Marie Stull,
Kaili Ren,
Vladimír Maisnar
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1225
Subject(s) - lenalidomide , ixazomib , medicine , multiple myeloma , dexamethasone , thalidomide , proteasome inhibitor , adverse effect , oncology , clinical trial , surgery , carfilzomib
Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov)